Evolution of the Average Target: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Average Target - Genmab A/S

Evolution of the Target Price: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Target Price - Genmab A/S

Changes in Analyst Recommendations: Genmab A/S

Data source: Genmab A/S(GMAB)
5cec4d41c2c94b7057e79b14295.WkF9wGEP5yYhiuld5OBUVo0eydmwO3sTcw62sB2uQus.NRkRp1FCqk9W5IUPrbMFG79Qipv0Wk1VOnfig2X6dIoVABGQMHqdcW7tng~0411ad8569b3079f1866a90e7079b31c
Oct. 14 UBS Raises Genmab Price Target to DKK 3,100 (2,700), Reiterates Buy FW
Oct. 13 BNP Paribas raises its price target for Genmab to DKK 2,850 (2,600), reiterates outperform - BN FW
Oct. 09 BofA 'Bullish' on Genmab's Upcoming Phase 3 Readouts; Buy Rating Maintained MT
Oct. 09 Deutsche Bank raises price target for Genmab to 3,000 Danish kroner, reiterates buy FW
Oct. 09 Deutsche Bank raises price target for Genmab to DKK 3,000 (2,750), reiterates buy FW
Oct. 08 Barclays raises price target for Genmab to DKK 3,100 (2,900), reiterates overweight FW
Oct. 07 Genmab: Beyond Darzalex Alphavalue
Oct. 07 Deutsche Bank Research Raises Genmab PT, Keeps Buy Rating MT
Oct. 07 Deutsche Bank reiterates buy on Genmab, raises price target to DKK 2,750 FW
Oct. 07 DNB Carnegie raises price target for Genmab to DKK 2,850 (2,300), reiterates buy FW
Oct. 06 Bank of America raises target price for Genmab to 2,850 Danish kroner (2,500), reiterates buy FW
Oct. 06 Deutsche Bank raises price target for Genmab to DKK 2,750 (2,500), reiterates buy FW
Oct. 06 Genmab in Good Health, Schneider Lacks Energy Zonebourse
Oct. 06 SEB reiterates Buy on Genmab, raises price target to DKK 3,000 (Update) FW
Oct. 06 SEB raises its price target for Genmab to DKK 3,000 (2,600), reiterates buy FW
Oct. 06 Barclays: Genmab's Epkinly beats expectations FW
Oct. 05 Jyske Bank downgrades Genmab to hold (buy), target price DKK2,350 - BN FW
Oct. 05 Guggenheim Securities raises price target for Genmab's American depositary receipts to $54 (45), reiterates buy FW
Oct. 05 Jefferies raises price target for Genmab to 2,900 Danish kroner (2,800), reiterates buy FW
Oct. 05 Barclays sees stronger phase 3 case for Genmab's Rina-S FW
Oct. 05 SEB raises price target for Genmab to DKK 2,775 (2,600), reiterates buy FW
Sep. 23 Kempen raises target price for Genmab: 'petosemtamab could be the biggest share-price driver in a decade' FW
Sep. 08 Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN FW
Sep. 03 Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo FW
Sep. 01 Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy FW

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+32.97%
+14.74%
+38.45%
+12.07%
+18.26%
+44.87%
+38.06%
+24.78%
+8.87%
Average +25.90%
Weighted average by Cap. +26.76%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
2,502.00DKK
Average target price
2,723.93DKK
Spread / Average Target
+8.87%
High Price Target
3,310.00DKK
Spread / Highest target
+32.29%
Low Price Target
2,050.00DKK
Spread / Lowest Target
-18.07%

Analyst Consensus Detail

Analyst consensus - Genmab A/S

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Genmab A/S
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Genmab A/S